JP2006501265A - 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト - Google Patents

嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト Download PDF

Info

Publication number
JP2006501265A
JP2006501265A JP2004535478A JP2004535478A JP2006501265A JP 2006501265 A JP2006501265 A JP 2006501265A JP 2004535478 A JP2004535478 A JP 2004535478A JP 2004535478 A JP2004535478 A JP 2004535478A JP 2006501265 A JP2006501265 A JP 2006501265A
Authority
JP
Japan
Prior art keywords
nicotine
administration
rats
threshold
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004535478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501265A5 (https=
Inventor
アティナ・マルコウ
ポール・ケニー
ニール・ペイターソン
スヴェトラーナ・セメノワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of JP2006501265A publication Critical patent/JP2006501265A/ja
Publication of JP2006501265A5 publication Critical patent/JP2006501265A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004535478A 2002-09-10 2003-09-10 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト Withdrawn JP2006501265A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40986702P 2002-09-10 2002-09-10
PCT/EP2003/010061 WO2004024150A2 (en) 2002-09-10 2003-09-10 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010113270A Division JP2010174039A (ja) 2002-09-10 2010-05-17 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
JP2013231434A Division JP2014074032A (ja) 2002-09-10 2013-11-07 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2006501265A true JP2006501265A (ja) 2006-01-12
JP2006501265A5 JP2006501265A5 (https=) 2006-10-26

Family

ID=31994019

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004535478A Withdrawn JP2006501265A (ja) 2002-09-10 2003-09-10 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
JP2010113270A Pending JP2010174039A (ja) 2002-09-10 2010-05-17 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
JP2013231434A Pending JP2014074032A (ja) 2002-09-10 2013-11-07 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010113270A Pending JP2010174039A (ja) 2002-09-10 2010-05-17 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
JP2013231434A Pending JP2014074032A (ja) 2002-09-10 2013-11-07 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト

Country Status (10)

Country Link
US (2) US8354447B2 (https=)
EP (1) EP1539149B1 (https=)
JP (3) JP2006501265A (https=)
CN (2) CN1694701A (https=)
AT (1) ATE539768T1 (https=)
AU (1) AU2003270166A1 (https=)
BR (1) BR0314192A (https=)
CA (1) CA2498022C (https=)
ES (1) ES2381664T3 (https=)
WO (1) WO2004024150A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
PT1578422E (pt) 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110151184A (zh) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 非接触式吸毒人员快速检测系统及方法
IL303248A (en) * 2020-12-11 2023-07-01 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
CN114088427A (zh) * 2021-11-22 2022-02-25 昆明理工大学 一种用于惯容器/悬架的性能测试试验台及试验方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066113A1 (en) * 2000-03-09 2001-09-13 Glaxo Group Limited Metabotropic glutamate receptor antagonists for treating tolerance and dependency

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014859A (pt) * 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
US6916821B2 (en) * 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066113A1 (en) * 2000-03-09 2001-09-13 Glaxo Group Limited Metabotropic glutamate receptor antagonists for treating tolerance and dependency

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6009059719; ＴＡＴＡＲＣＺＹＮＳＫＡ，Ｅ．　ｅｔ　ａｌ: 'Ｐｏｔｅｎｔｉａｌ　ａｎｘｉｏｌｙｔｉｃ-　ａｎｄ　ａｎｔｉｄｅｐｒｅｓｓａｎｔ-ｌｉｋｅ　ｅｆｆｅｃｔｓ　ｏｆ　ＭＰＥＰ，　ａ　ｐｏｔｅｎｔ，　ｓｅｌｅｃｔｉｖｅ　ａｎｄ　ｓｙｓｔｅｍｉｃａｌｌｙ' Ｂｒ　Ｊ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．１３２，　Ｎｏ．７, 2001, ｐ．１４２３-３０ *
JPN6009059721; ＦＵＮＤＹＴＵＳ，Ｍ．Ｅ．　ｅｔ　ａｌ: 'Ａｔｔｅｎｕａｔｉｏｎ　ｏｆ　ｍｏｒｐｈｉｎｅ　ｗｉｔｈｄｒａｗａｌ　ｓｙｍｐｔｏｍｓ　ｂｙ　ｓｕｂｔｙｐｅ-ｓｅｌｅｃｔｉｖｅ　ｍｅｔａｂｏｔｒｏｐｉｃ　ｇｌｕｔａｍａｔｅ　ｒｅｃｅｐｔｏｒ　ａｎｔ' Ｂｒ　Ｊ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．１２０，　Ｎｏ．６, 1997, ｐ．１０１５-２０ *
JPN6013020409; 現代医療 Ｖｏｌ．３３　Ｎｏ．１１, 200111, ｐ１２０-１２５
JPN6013020410; Ｎｅｕｒｏｐｈａｒｍａｃｏｌｏｇｙ ＶＯＬ．３８　Ｎｏ．２, 199902, ｐ２１７-２２２
JPN6013020411; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．１２１　Ｎｏ．３, 1997, ｐ５１１-５１４
JPN7009005005; ＷＡＴＥＲＨＯＵＳＥ、Ｒ．Ｎ．　ｅｔ　ａｌ: 'Ｉｎ　ｖｉｖｏ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　ｔｈｅ　ｍＧｌｕＲ　ａｎｔａｇｏｎｉｓｔ　［３Ｈ］Ｌｙ３４１４９５' Ｓｏｃｉｅｔｙ　ｆｏｒ　Ｎｅｕｒｏｓｃｉｅｎｃｅ　Ａｂｓｔａｒａｃｔｓ Ｖｏｌ．２７，　Ｎｏ．２, 2001, ２３５８（８８９．９） *

Also Published As

Publication number Publication date
CA2498022C (en) 2012-10-23
WO2004024150A2 (en) 2004-03-25
JP2010174039A (ja) 2010-08-12
US8354447B2 (en) 2013-01-15
ATE539768T1 (de) 2012-01-15
AU2003270166A8 (en) 2004-04-30
EP1539149B1 (en) 2012-01-04
ES2381664T3 (es) 2012-05-30
CA2498022A1 (en) 2004-03-25
AU2003270166A1 (en) 2004-04-30
JP2014074032A (ja) 2014-04-24
CN1694701A (zh) 2005-11-09
US20130210849A1 (en) 2013-08-15
CN102793698A (zh) 2012-11-28
US20060148835A1 (en) 2006-07-06
EP1539149A2 (en) 2005-06-15
BR0314192A (pt) 2005-07-26
WO2004024150A3 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
US8354447B2 (en) mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression
Posadas et al. Nicotinic receptors in neurodegeneration
Preti New developments in the pharmacotherapy of cocaine abuse
JP6676062B2 (ja) 認知低下を処置するための方法
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
Johnson et al. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies
JP2010523587A (ja) 治療処置の副作用の低減のための方法および組成物
AU2024266870A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2008083442A1 (en) Method for formulating combination medications for adhd
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP2413935A1 (en) Low dose pipamperone in treating mood disorders
Frishman Smoking cessation pharmacotherapy
Geste et al. Self-administration of the synthetic cathinone MDPV enhances reward function via a nicotinic receptor dependent mechanism
JP2008507577A (ja) 中枢神経系の障害を治療するための医薬
JP2024507492A (ja) 精神療法を補助するためのメスカリン及びメスカリン類似体（スカリン）の効果
Fornal et al. Pindolol, a Putative 5-Hydroxytryptamine1AAntagonist, Does Not Reverse the Inhibition of Serotonergic Neuronal Activity Induced by Fluoxetine in Awake Cats: Comparison to WAY-100635
Lotfipour et al. The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition
CN103877096B (zh) 盐酸氯卡色林在制备抑制阿片类物质成瘾和戒断反应的药物中的应用
CN1226165A (zh) 治疗双相情感障碍的方法
Kenny et al. Group II metabotropic and AMPA/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response patterns
Jiang Alterations of monoaminergic systems by sustained triple reuptake inhibition
Haro et al. Pharmacological treatment of substance dependence from a neuroscientific perspective (II): alcohol, benzodiazepines and nicotine
Lorenzo-Trujillo Are smoking cessation methods as successful in reaching long term abstinence rates when used by smokeless tobacco users in the United States
POHAR Sustained-Release (SR) Bupropion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140326